GlassScriptPhysician profile
Michael L Douglas
NPI 1902169543
$6,327.09
in general payments reported to CMS, 2019-2025
32 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $1,263 · 2021: $530 · 2022: $1,647 · 2023: $366 · 2024: $515 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849 · Travel and Lodging: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.89 |
| Travel and Lodging | $230.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,448.82 | 2019-2024 | Greenlight Xps |
| Neotract INC. | $1,384.79 | 2019-2020 | |
| Teleflex LLC | $1,269.45 | 2021-2023 | Urolift |
| Procept Biorobotics Corporation | $678.87 | 2024-2025 | Aquabeam System |
| Astellas Pharma US INC | $414.79 | 2019-2023 | Myrbetriq |
| Urovant Sciences INC | $261.68 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.87 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $97.54 | 2023 | Gemtesa |
| Coloplast Corp | $71.54 | 2019-2021 | |
| Axonics, INC. | $64.46 | 2020-2022 | |
| Janssen Biotech, INC. | $45.09 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $43.91 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $42.96 | 2019-2021 | |
| Halozyme INC | $34.50 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $31.59 | 2022-2023 | Seglentis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $30.22 | 2019 | |
| Pfizer INC. | $28.86 | 2019-2022 | |
| Zyla Life Sciences, INC. | $25.73 | 2019 | |
| Abbvie INC. | $22.29 | 2022 | |
| Dendreon Pharmaceuticals LLC | $21.87 | 2023 | Provenge |
| Blue Earth Diagnostics | $16.29 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.13 | 2021 | |
| Ambu INC. | $16.12 | 2021 | |
| Axogen | $14.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.51 | 2022 | |
| Allergan, INC. | $14.33 | 2021 | |
| Myovant Sciences INC. | $14.26 | 2022 | |
| Medtronic USA, INC. | $13.31 | 2019 | |
| Cook Medical LLC | $12.35 | 2021 | |
| Shire North American Group INC | $11.56 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.46 | 2019 | |
| Medtronic, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.